A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone

BACKGROUND: Cardiac pathological hypertrophy is associated with a significantly increased risk of coronary heart disease and has been observed in diabetic patients treated with rosiglitazone whereas most published studies do not suggest a similar increase in risk of cardiovascular events in pioglita...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschuren, Lars, Wielinga, Peter Y, Kelder, Thomas, Radonjic, Marijana, Salic, Kanita, Kleemann, Robert, van Ommen, Ben, Kooistra, Teake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072889/
https://www.ncbi.nlm.nih.gov/pubmed/24938300
http://dx.doi.org/10.1186/1755-8794-7-35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072889/
https://www.ncbi.nlm.nih.gov/pubmed/24938300
http://dx.doi.org/10.1186/1755-8794-7-35

Ejemplares similares